Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections... Show more
MRK is expected to report earnings to rise 13.15% to $2.41 per share on October 30
Q3'25
Est.
$2.41
Q2'25
Beat
by $0.10
Q1'25
Beat
by $0.08
Q4'24
Missed
by $0.09
Q3'24
Beat
by $0.07
The last earnings report on July 29 showed earnings per share of $2.13, beating the estimate of $2.03. With 10.77M shares outstanding, the current market capitalization sits at 331.75B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MRK showed earnings on July 29, 2025. You can read more about the earnings report here.